R1 Rcm Inc. RCM
We take great care to ensure that the data presented and summarized in this overview for R1 RCM Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding RCM
View all-
New Mountain Vantage Advisers, L.L.C. New York, NY94.4MShares$1.19 Billion40.72% of portfolio
-
Black Rock Inc. New York, NY16.7MShares$211 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA15.1MShares$190 Million0.0% of portfolio
-
Coliseum Capital Management, LLC Rowayton, CT10.3MShares$130 Million12.93% of portfolio
-
Voss Capital, LLC Houston, TX9.21MShares$116 Million11.21% of portfolio
-
State Street Corp Boston, MA5.27MShares$66.6 Million0.0% of portfolio
-
Hawk Ridge Capital Management LP Los Angeles, CA4.61MShares$58.2 Million2.86% of portfolio
-
Paradigm Capital Management Inc4.45MShares$56.2 Million2.77% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.32MShares$54.6 Million0.01% of portfolio
-
American Century Companies Inc Kansas City, MO4.06MShares$51.2 Million0.03% of portfolio
Latest Institutional Activity in RCM
Top Purchases
Top Sells
About RCM
R1 RCM Inc. provides technology-driven solutions that transform the patient experience and financial performance of hospitals, health systems, and medical groups. It offers end-to-end revenue cycle management (RCM) services, which address the spectrum of revenue cycle challenges faced by healthcare providers. The company also provides modular services, including physician advisory services, which assists healthcare organizations in complying with payer requirements regarding whether to classify a hospital visit as an in-patient or an out-patient observation case for billing purposes; practice management services that offers administrative and operational support for patient care and outsource non-core functions; revenue integrity solutions, including charge capture, charge description master maintenance, and pricing services; coding management services, such as business intelligence and analysis, human capital management, accountability framework, and quality management programs; patient experience; and business office services. In addition, the company offers software-as-a-service based scheduling and patient access solutions. The company was founded in 2003 and is headquartered in Murray, Utah.
Insider Transactions at RCM
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jun 01
2024
|
John M. Sparby President |
BUY
Grant, award, or other acquisition
|
Direct |
29,160
+9.07%
|
-
|
Jun 01
2024
|
Pamela L. Spikner Principal Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,895
+6.41%
|
-
|
Jun 01
2024
|
Lee Rivas Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
118,973
+23.51%
|
-
|
Jun 01
2024
|
Kyle Hicok Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
28,927
+35.4%
|
-
|
Jun 01
2024
|
Jennifer D. Williams Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,241
+35.4%
|
-
|
May 23
2024
|
Anthony R Tersigni Director |
BUY
Grant, award, or other acquisition
|
Direct |
22,241
+13.19%
|
$133,446
$6.07 P/Share
|
May 23
2024
|
Jill D. Smith Director |
BUY
Grant, award, or other acquisition
|
Direct |
22,241
+15.72%
|
$133,446
$6.07 P/Share
|
May 23
2024
|
Joseph Gerard Flanagan Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,651
+0.46%
|
-
|
May 23
2024
|
Jeremy Delinsky Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,651
+36.72%
|
-
|
May 23
2024
|
David M Dill Director |
BUY
Grant, award, or other acquisition
|
Direct |
22,241
+19.23%
|
$133,446
$6.07 P/Share
|
May 23
2024
|
Bradford Kyle Armbrester Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,651
+36.72%
|
-
|
May 23
2024
|
Anthony J Speranzo Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,594
+20.98%
|
-
|
May 23
2024
|
Michael C. Feiner Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,651
+20.41%
|
-
|
May 23
2024
|
Scanlan Agnes Bundy Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,651
+32.16%
|
-
|
May 23
2024
|
John B Henneman Iii Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,651
+15.13%
|
-
|
Mar 11
2024
|
John M. Sparby President |
SELL
Other acquisition or disposition
|
Direct |
3,101
-1.17%
|
-
|
Mar 07
2024
|
John M. Sparby President |
SELL
Open market or private sale
|
Indirect |
10,046
-100.0%
|
$140,644
$14.33 P/Share
|
Mar 06
2024
|
John M. Sparby President |
SELL
Other acquisition or disposition
|
Direct |
3,750
-1.39%
|
-
|
Feb 27
2024
|
Joseph Gerard Flanagan Director |
SELL
Payment of exercise price or tax liability
|
Direct |
55,825
-1.63%
|
$781,550
$14.58 P/Share
|
Feb 27
2024
|
Joseph Gerard Flanagan Director |
BUY
Grant, award, or other acquisition
|
Direct |
148,849
+4.16%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 604K shares |
---|---|
Exercise of conversion of derivative security | 50K shares |
Open market or private sale | 60K shares |
---|---|
Payment of exercise price or tax liability | 66.6K shares |
Other acquisition or disposition | 6.85K shares |